BioSpace News Archive

According to the global Nuclear Medicine market size was estimated at USD 9.50 billion in 2021 and is expected to surpass around USD 25.40 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 11.9% during the forecast period 2022 to 2030.

Sirnaomics Ltd. (the “Company” or “Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it will present the latest developments on delivery of novel RNAi therapies for cancer, and its GalAhead™ platform and programs, at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference.

The global Point of Care Molecular Diagnostics market size was estimated at USD 2.18 billion in 2021 and is expected to surpass around USD 10.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 14.5% during the forecast period 2022 to 2030.

According to Nova one advisor, the global In Vitro Fertilization /IVF market was valued at USD 638 million in 2021 and it is expected to hit around USD 2.4 billion by 2030 with a CAGR of 14.9% during the forecast period 2022 to 2030.

According to Nova one advisor, the global Multiplex Assays market was valued at USD 3.4 billion in 2021 and it is expected to hit around USD 6.3 billion by 2030 with a CAGR of 7.6% during the forecast period 2022 to 2030

Shanghai Junshi Biosciences Co., Ltd announced that the China National Medical Products Administration has approved the supplemental new drug application for toripalimab in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer.

Oncopeptides AB announces that the US Food and Drug Administration, has published the Briefing Book for the Oncologic Drugs Advisory Committee meeting on September 22, 2022.

Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced that it will be participating in the Lytham Partners Fall 2022 Investor Conference, taking place virtually on September 28-29, 2022.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of the American Medical Association (JAMA) published positive results from two pivotal Phase 3 studies (DERMIS-1 and DERMIS-2) evaluating roflumilast cream 0.3% as a once daily, topical treatment for chronic plaque psoriasis.

The Center for Breakthrough Medicines (CBM) and jCyte today announced a multi-year manufacturing agreement wherein CBM will be the primary manufacturer of jCyte’s U.S. Food & Drug Administration’s Regenerative Medicine Advanced Therapy (RMAT) designated cell therapy, jCell.